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ABSTRACT 
The aim of the present work is to study the preformulation parameters for Transdermal drug delivery system. The objective of 
Preformulation study is to generic information useful to the formulater in developing stable and bioavailable dosage form. The use of 
Preformulation parameter maximizes the chances in formulation an acceptable, safe, efficacious and stable product and at the same 
time provide the basis for optimization of the drug product quality. Administration of conventional tablets of repaglinide has been 
reported to exhibit fluctuations in plasma drug levels, resulting either in manifestation of side effects or reduction in drug 
concentration at the receptor sites also, the maintenance of a constant plasma concentration of a anti-diabetic drug is important in 
ensuring the desired therapeutic response, again since the half life of repaglinide is  01 hour hence multiple doses of the drug are 
needed to maintain a constant plasma concentration for a good therapeutic response, and improve patient compliance, hence the 
objective of the study was made to develop controlled release Transdermal Drug Delivery System of repaglinide using polymer like 
Eudragit RS 100, Eudragit RL 100 and HPMC, which will controlled the release of drug, increasing the bioavailability of the drug 
and thus decreasing the dosing frequency of the drug. The Preformulation studies were carried out in terms of test for identification 
(physical appearance, melting point, and uv spectrophotometer), solubility profile, determination of partition coefficient and 
quantitative estimation of drug. All the observation and results showed that the repaglinide could serve as suitable candidate for 
Transdermal drug delivery system that may improve the bioavailability. 
Keywords: Transdermal, Repaglinide, Preformulation, Half Life, bioavailability 
 
Article Info: Received 08 May, 2017; Review Completed 11 July, 2017; Accepted 12 July, 2017; Available online 15 July, 2017 
Cite this article as: 
Sahu M, Bhowmick M, Rathi J,preformulation screening of repaglinide for transdermal anti-diabetic 
therapy, Journal of Drug Delivery and Therapeutics. 2017; 7(4):103-109 
DOI: http://dx.doi.org/10.22270/jddt.v7i4.1460  
*Address for Correspondence  
Mithilesh Sahu, NRI Institute of Pharmaceutical Sciences, Bhopal, India. Email: mithun211@gmail.com 
 
 
INTRODUCTION 
The advantages of transdermal drug delivery system 
(TDDS) include the control of drug release, prolongation 
of steady-state plasma concentration with much less 
peak and-trough variation, improving the safety and 
patient convenience. Intensive research has showed that 
transdermal route is a potential mode of delivery of 
lipophillic drugs in the systemic circulation. Matrix 
based transdermal formulations have been developed for 
a number of drugs such as Nitroglycerine and Ephedrine.
 
1-2
 Diabetes mellitus is a major and growing health 
problem worldwide and an important cause of prolonged 
illness and early death. It is a chronic metabolic disorder 
characterized by a high blood glucose concentration 
(hyperglycemia) caused by insulin deficiency, and it is 
often combined with insulin resistance. Repaglinide, a 
carbamoylmethyl benzoic acid derivative, is the first of a 
new class of oral antidiabetic agents designed to 
normalise postprandial glucose excursions in patients 
with Type 2 Diabetes Mellitus. Like the Sulphonylureas, 
Repaglinide acts by stimulating release of insulin from 
the β-cells of the pancreas. Repaglinide is rapidly and 
completely absorbed, with maximum plasma 
concentrations (Cmax) occurring aproximatly within an 
hour after oral administration. It possesses low oral 
bioavailability (56%) due to hepatic first pass 
metabolism after oral administration and has a short 
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biological half life of 1h which makes frequent dosing 
0.5 to 4 mg in 3 to 4 times in a day necessary to maintain 
the drug within the therapeutic blood levels for long 
periods. It has melting point of 130-131
 o
C, short half 
life (1 hr), Mol. wt. 452.584 and lipophilicity log P value 
3.97. Hence, Repaglinide is an ideal drug candidate for 
transdermal drug delivery. The purpose of the present 
work was to undertake the preformulation study of 
Repagliide for transdermal     delivery. 
3-10
 
The objective of Preformulation study is to generic 
information useful to the formulater in developing stable 
and bioavailable dosage form. The use of Preformulation 
parameters maximizes the chances in formulation for an 
acceptable, safe, efficacious and stable product and at 
the same time provides the basis for optimization of the 
drug product quality. The Preformulation studies were 
carried out in terms of test for identification (physical 
appearance, melting point, and uv spectrophotometer), 
solubility profile, determination of partition coefficient 
and quantitative estimation of drug. 
MATERIALS & METHODS  
Materials 
Repaglinide was obtained as a gift sample from Alkem 
Laboratories, Mumbai. Eudragit RS 100, Eudragit 
RL100 & HPMC from Evonik Degussa India pvt. Ltd., 
Mumbai. Double Distilled water was used throughout 
the study & all other chemicals and solvents were 
analytical reagent grade and purchased from commercial 
suppliers. 
Methods 
Pre-Formulation Studies 
Organoleptic Properties of drug 
13,14
  
Color: A small quantity of the drug was taken on butter 
paper and viewed in well- illuminated place. 
Odor: Very less quantity of the drug was smelled to get 
the odor. 
Taste
:
 Very less quantity of the drug was put on tongue 
to get the taste. 
Solubility 
6,11,15,16
  
The spontaneous interaction of two more substances to 
form a homogenous molecular dispersion is known as 
solubility. 
The sample was qualitatively tested for its solubility in 
various aqueous and non-aqueous solvents at room 
temperature. 
Method 
 Weight 100 mg finally powdered substance in a 
stoppered tube (16 mm in internal diameter and 160 
mm long) added 0.1 ml of solvent if the substance 
was completely dissolve, it was very soluble. 
 If not completely dissolved added 0.9 ml of solvent 
if substance was completely dissolved it was freely 
soluble. 
 If not completely dissolved added 2 ml of solvent if 
substance was completely dissolve it was soluble. 
 If not completely dissolved added 7 ml of solvent if 
substance was completely dissolve it was sparingly 
soluble. 
 If not completely dissolve added 10 ml of solvent if 
substance was completely dissolved it was slightly 
soluble. 
If not completely dissolved weight 1 mg of finely 
substance in stoppered tube, add 10 ml of the solvent it 
was very slightly soluble 
  
Table No.1: Descriptive terms of Solubility and their Qualitative designations 
S.No. Descriptive terms Approximate volume of solvent in milliliters per gram of solute. 
1 very soluble less than 1 
2 freely soluble from 1 to 10 
3 Soluble from 10 to 30 
4 sparingly soluble from 30 to 100 
5 slightly soluble from 100 to 1000 
6 very slightly soluble from 1000 to 10,000 
7 practically insoluble more than 10,000 
 
Partition coefficient 
6,11,15,16
 
The partition studies were conducted by shake flask 
method. n-octanol was saturated with phosphate buffer, 
pH 7.4 for 24 hours before the experiment. Accurately 
weighed amount about, 10 mg of repaglinide was added 
to each 20 mL of n-octanol and phosphate buffer, pH 
7.4 mixture (1:1 ratio). n-octanol layer was less dense 
than PBS pH 7.4, so the n-octanol layer was on the top 
of the phosphate buffer, pH 7.4. The solution was kept 
for 24 hours shaking at room temperature on rotary 
shaker. Two phases were separated through separating 
funnel and filtered through whatman filter paper. The 
concentration of the drug in the aqueous phase was 
analyzed against reagent blank on a double beam UV/ 
visible spectrophotometer at 288 nm; concentration of 
the drug in n-octanol was calculated from the difference 
between the initial amount and amount in aqueous 
phase. The partition coefficient (Po/w) of Repaglinide 
was calculated from the ratio between the concentration 
of MT in organic (Coil) and aqueous phase (Caq.) using 
following equation. 
Po/w = (Coil/Caq.) equilibrium 
Usually expressed in a logarithmic scale, log P refers to 
partitioning of unionized species. Lipophilicity (log P) is 
represented by logarithm of partition coefficient in 
octanol/PBS 7.4. 
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Melting Point 
6,11,17,18
  
Melting point of the drug was determined by capillary 
method using Melting point apparatus. Here, the 
capillary tube was filled by pressing the open end gently 
into sample by tapping the bottom of the capillary on a 
hard surface so that the drug pack down into the bottom 
of the tube. When the drug packed into the bottom of the 
tube, the tube was placed into the slot behind the eye-
piece on the Melt-temperature. Make sure the unit is 
plugged in and set to zero, and then turn it on. The 
temperature were noted when the drug start to melt and 
the drug till complete melt.
 
Loss on drying (% LOD) 
6,11,15,16
 
1gm of the pure drug sample was transferred to the glass 
stoppered shallow weighing bottle. Before keeping the 
drug sample, the weighing bottle has been dried for 60 
minutes under the same conditions to be employed in 
the determination.  It was then cooled in a desiccator. 
The empty bottle was weighed (W1). The sample was 
kept in the bottle, replaced the cover, and accurately 
weighed the bottle and the contents (W2). By gentle, 
sidewise shaking, distributed the sample as evenly as 
practicable to a depth of about 5 mm. placed the loaded 
bottle in the drying chamber (drying oven) at 60
o
C for 4 
hours. The bottle was weighed every hour until a 
constant weight was obtained (W3). The loss on drying 
is calculated by the formula  
                                         % LOD =   (W2-W3/W2-
W1)×100 
Analytical Method used in The Determination of 
Repaglinide
6,11,12
 
 
The UV spectrophotometry method was developed for 
the analysis of drug using double beam Shimadzu 
spectrophotometer. Repaglinide was dissolved in 30% 
v/v Methanolic isotonic phosphate buffer (MIPB) pH 
7.4. and determination of λmax and standard graph of 
Repaglinide was determined. 
Procedure: 
Determination of λmax 
Repaglinide was dissolved in MIBS pH 7.4 and further 
diluted with the same and scanned for maximum 
absorbance in UV double beam spectrophotometer 
[Shimandzu- 1700] in the range from 190 to 380 nm, 
using MIBS pH 7.4 as blank.  
Standard graph of Repaglinide 
Accurately weighed 10 mg of drug was dissolved in 10 
ml of MIBS (7.4 pH) to get 1000μg/ml. Then prepare 
suitable dilution of sample with concentration range of 
5-25μg/ml. The spectrum of this solution was run in 190 
to 380  nm range in U.V spectrophotometer. 
Drug Polymer Compatibility study 
6,11,13-18
 
FTIR Analysis 
FTIR spectra of pure drug Repaglinide, polymers 
(Eudragit RS 100, Eudragit RL 100 & HPMC) and 
mixture of drug and polymers were carried out by FT-IR 
spectrophotometer. The IR spectra were recorded using 
IR Spectrophotometer by KBr pellet method.  
RESULT AND DISCUSSION 
Pre-Formulation Studies 
Organoleptic Properties of drug  
Drug repaglinide was found to be white crystalline 
powder, odorless and Tasteless. The drug was found to 
comply with the literature specifications. The table 
below shows the organoleptic properties of the drug.
 
Table 2: Organoleptic Properties of drug 
S.No. Test Specification Practical Observation 
1. Color White crystalline powder White crystalline Powder 
2. Odour Odourless Odourless 
3. Taste Tasteless  Tasteless 
 
Melting Point 
The melting point of repaglinide has been observed to 
melt close to literature specification range. 
Table 3: Melting Point of drug 
Test 
Specification 
(Range) 
Practical 
Observation 
(Range) 
Melting 
Point 
   130-135
 o
C   131-135
o
C 
 
Solubility 
The drug Repaglinide was found to be freely soluble in 
acetone and Phosphate buffer pH 9.0. The dug was 
found to be soluble in Ethanol, Methanol, 
Dichloromethane and chloroform, Phosphate buffer pH 
7.4, slightly soluble in distilled water, insoluble in 
Phosphate buffer pH 1.0. The drug was found to comply 
with the literature specifications. 
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Table 4: Solubility of drug in different solvents 
S.N. SOLVENT SOLUBILITY RESULT 
1 Acetone Freely soluble ++++ 
2 Dichloromethane  Soluble +++ 
3 Ethanol (95%) Soluble +++ 
4 Methanol Soluble +++ 
5 CHCL3 Soluble +++ 
6 Distilled Water Slightly soluble ++  
7 Phosphate buffer pH 1.0 Insoluble - - - 
8 Phosphate buffer pH 7.4 Soluble +++ 
9 Phosphate buffer pH 9.0 Freely soluble +++++ 
Very soluble                   Less than 1                    +++++ 
Freely soluble                 1-10 Parts                      ++++ 
Soluble                            10-30 Parts                   +++ 
Sparingly soluble            30-100 Parts                  ++ 
Slightly soluble          100-1000 Parts              + 
Practically insoluble        greater than 1000         - - - 
 
Partition coefficient 
The partition coefficient of the drug was conducted by 
shake-flask method and was found to be                           
3.81± 0.015.   The drug was found to comply with the 
literature specifications. It showed that drug lipophilic in 
nature. 
Table 5: Partition Coefficient of the drug 
Solvent System Partition Coefficient 
Mean±SD 
n-octanol: phosphate buffer, 
pH 7.4 
3.81 ± 0.015 
SD: Standard Deviation; n=3 
 Loss on drying (%): The Percentage loss on drying for 
repaglinide was found to be 0.31% w/w±0.021. The % 
LOD was found to be under the limit as per the 
literature. 
Table 6: Loss on drying (%) of the drug 
Loss on drying (%) 
Specification as per literature 
Loss on drying (%) 
Mean±SD 
The loss should not be more than 
0.5% 
0.31±0.021  
SD: Standard Deviation; n=3 
Analytical Method used in the Determination of 
Repaglinide 
Determination of λmax 
The λ max of the drug was found to be 288 nm. 
 
Figure 1: λ max of the Drug 
 
Figure 2:  Standard graph of Repaglinide 
 
 
Figure 3:  3D Standard graph of Repaglinide 
Drug Polymer Compatibility study 
As described in the methodology section the Fourier 
Transform infrared spectroscopy studies were carried out 
for pure drug and along with polymers. The results are 
summarized as follows. IR spectra of drug repaglinide 
and polymers Eudragit RL 100, Eudragit RS 100  and 
HPMC alone and  their combinations are shown in 
Figures. 
 
y = 0.0244x - 0.0019 
R² = 0.9998 
-0.5 
0 
0.5 
1 
0 10 20 30 
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Table 7: Major peak observed in the FTIR 
spectrum 
Bands Wave number(cm
-1
) 
OH (Str.) 3411.04 
CH Aromatic (Str.) 2960.42 
CH Aliphatic (Str.) 2915.38 
C=O (Str.) 1667.03 
C-O-C (Str.) 1260.78 
C - N (Str.) 1314.97 
 
The appearance or disappearance of peaks and/or the 
shift of their positions are often indications of 
interactions such as hydrogen bonding. Repaglinide 
presented characteristic peak at 3411.04 cm
-1
 due to OH 
stretching, 2990 cm
-1
 was due to CH aromatic stretching 
vibration and in 2915.98 due to CH aliphatic stretching 
vibration. C-O-C (Str.) shows the peak at 1260.78 cm
-1
, 
peak at 1414.97 cm
-1
 was due to C - N scissor stretching 
vibration. When the data obtained from FTIR spectra is 
compared with the standard spectra it was observed that 
there are similar peaks for functional groups in 
repaglinide, this shows the purity of repaglinide. 
FT-IR spectra of standard drug exhibited C-O-C (Str.) 
peak at 1260.78 cm
-1
 & peak at 1414.97 cm
-1
 was due to 
C - N scissor stretching vibration. The mixture of drug 
and excipients which was kept in accelerated condition 
of 40
0
C/ 75% RH for 30 days and subjected to FT-IR 
analysis. The characteristic peak of C-O-C (Str.) & C - N 
does not deviated from its position that predicts that 
there is no interaction between drug and excipients. 
 
 
 
Figure 4: FTIR of Repaglinide 
 
 Figure 5: FTIR of HPMC 
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Figure 6: FTIR of EUDRAGIT RS100 
+ 
 Figure 7: FTIR of EUDRAGIT RL100 
 
Figure 8: FTIR of Drug-Polymer Mixture 
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CONCLUSION 
Transdermal drug delivery system promises many 
advantages over oral and/or inravenous 
administration,such as better control of blood levels,a 
reduced incidenc of systemic toxicity and absence of 
hepatic first pass metabolism.An ideal drug to be 
formulated as transdermal drug delivery should posses 
several physico-chemical prerequisites,such as short half 
life,small molecular size,low dose etc. The present 
investigation was aimed to evaluate the possibility of 
using different parameters for the development of 
transdermal delivery of repaglinide, an anti-diabetic 
drug. Preformulation studies were done using various 
parameters such as the description and appearance, 
melting point and solubility, FT-IR, analytical UV 
method were performed for characterization & it was 
found that all results were satisfactory. 
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